Price Chart
Insider Transactions
| Date | Insider | Dir. | Shares | Value |
|---|---|---|---|---|
| Aug 21, 2026 | Loxam, Teri | Sell | 13,333 | — |
| Aug 21, 2026 | Loxam, Teri | Buy | 13,333 | — |
| Aug 21, 2026 | Chao, Jennifer M. | Sell | 13,333 | — |
| Aug 21, 2026 | Chao, Jennifer M. | Buy | 13,333 | — |
Score uses open-market buys only
· 0 open-market
· 2 plan / compensation shown but not scored
· Return is unrealized, to today's price; a
“· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.
Score Breakdown
| Component | Points | Max |
|---|---|---|
| Conviction (unique buyers) ✓ FREE PREVIEW | 20 | 30 |
| Buy/sell ratio | 20 | |
| Dollar value | 25 | |
| Lobbying activity | 15 | |
| Contract wins | 10 | |
| Insider track record | 10 | |
| Private placements | 8 | |
| Confluence bonus | 10 | |
| Cluster timing (velocity) | 10 | |
| Buy/sell reversal pattern | 8 | |
| Total | 45 | 100 |
Lobbying Registrations
No active OCL lobbying registrations in the last 90 days.
Analyst plan →
Government Contract Wins
No government contract wins in the last 90 days.
Analyst plan →
Private Placements
Private placement history, deal size, and lock-up expiry tracking.
Analyst plan →
Political Footprint
1 insider linked to CRDL is also individual political donor — $2K across 5 donations (2007–2012).
Conservative Party of Canada · $2K
Sources: Elections Canada (individual donations only — corporate political donations banned federally since 2007), the federal Registry of Lobbyists, and federal contract disclosures. Insiders matched to donors by name. Shown for transparency from disclosed public records — this is not a Confluence Score input, implies no causal link between donations, lobbying, or contracts, and is not a claim of wrongdoing.
Indigenous Consultation
No Indigenous consultation records on file for CRDL.
SEDAR+ Filings
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes.
Search SEDAR+ →
Short Interest
Shares short
765,657
Net change
+9,849
(+1.3%)
History
Sep 15:
765,657
Aug 31:
755,808
Aug 15:
354,081
Jul 31:
183,673
Jul 15:
196,584
Jun 30:
172,461
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Clinical Trials
| Phase | Status | Trial |
|---|---|---|
| P3 | Recruiting | CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) |
| P2 | Completed | Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myoc |
| P2 | Completed | Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) |
| P2/P3 | Terminated | Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Ri |
Trials where this company is the lead sponsor (ClinicalTrials.gov). Phase advances, completions and
terminations are material catalysts for clinical-stage companies — not investment advice.